Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study

Plett, Helmut; Filippova, Olga T.; Garbi, Annalisa; Kommoss, Stefan; Rosendahl, Mikkel; Langstraat, Carrie; Phadnis, Saurabh; Muallem, Mustafa Zelal; Baert, Thaïs; Dennis, S.; Aletti, Giovanni; Taran, Florin Andrei; Ramspott, Jan Philipp; Zivanovic, Oliver; Bois, Andreas du; Sonoda, Yukio; Gardner, Ginger J.; Traut, Alexander; Roche, Kara Long; Harter, Philipp

doi:10.1016/j.ygyno.2020.08.028

Cited by 16 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Residual tumor is also a very important risk factor and a fatal factor. Patients with few residual tissues will have a high survival rate and benefit prognosis [ 20 ]. Physicians have been trying to find better treatment strategies, hoping to detect the occurrence of OC at an early stage, to avoid the regrowth of the tumor as well as to improve the survival rate of patients.…”

Section: Discussionmentioning

confidence: 99%

MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A

Wang¹,

Liu²

2021

J Ovarian Res

View full text Add to dashboard Cite

Background Ovarian cancer (OC), a kind of gynecological cancer, is characterized by high mortality rate, with microRNAs (miRNAs) playing essential roles in it. However, the clinical significance of miRNAs and their molecular mechanisms in OC are mostly unknown. Methods miR-149-3p expression was predicted through Gene Expression Omnibus (GEO) data in OC and confirmed by q-PCR in various OC cells and tissues from patients with different clinical characteristics. Moreover, its roles in terms of proliferation, migration and invasion were measured by CCK-8, colony formation, wound healing and transwell assays in OC cells including cisplatin-resistant and cisplatin-sensitive cells. And its effect on epithelial-mesenchymal transition was also assessed through detecting related protein expression. Additionally, its potential targets were verified by dual luciferase assay and Ago-RIP assay. Finally, its oncogenic functions were explored in vivo. Results In data from GSE79943, GSE131790, and TCGA, miR-149-3p was found to be highly expressed in OC tissues and associated with poor survival. In metastasis and chemoresistant tissues and cisplatin-resistant OC cells, its high expression was confirmed. In terms of tumorigenic effects, miR-149-3p knockdown in cisplatin-resistant OC cells inhibited its cisplatin resistance and other malignant phenotypes, while miR-149-3p overexpression in cisplatin-resistant OC cells led to contrary results. Mechanistically, miR-149-3p targeted 3’UTR of CDKN1A and TIMP2 to function as an oncogenic miRNA. Conclusion In brief, miR-149-3p promoted cisplatin resistance and EMT in OC by downregulating CDKN1A and TIMP2, which might provide a potential therapeutic target for OC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A

Wang¹,

Liu²

2021

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…We did not find that more cycles of pre-operative chemotherapy significantly impacted the rates of bowel resection at interval cytoreduction, although this may have been due to insufficient power. Recent studies have demonstrated a survival benefit to giving more than the standard three cycles of chemotherapy if it enables a complete cytoreduction at interval surgery; ( Phillips et al, 2018 , Plett et al, 2020 ) however, giving five or more cycles may convey worse prognosis even with maximal cytoreduction ( Liu et al, 2020 ). There may be further benefit to giving additional cycles if patients have a response to initial cycles of neoadjuvant chemotherapy yet are thought to remain at high risk for requiring a bowel resection.…”

Section: Discussionmentioning

confidence: 99%

Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer

McNamara

Guerra

Qin

et al. 2021

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Highlights Bowel resection is associated with decreased three-year survival. Bowel resection does not impact progression free survival. Bowel resection is associated with significant peri -operative complication. Sequelae of peri -operative morbidity may contribute to decreased survival. Bowel resection may be a surrogate for worse tumor molecular subtype.

show abstract

“…The median survivals used in the power calculation have been determined using weighted means from published data. [2][3][4][5][6][7][8][9][10][11][12][15][16][17][18] Current evidence on the survival following interval and delayed cytoreductive surgery does not allow to produce a non-inferiority/equivalence sample size calculation to support our hypothesis that the survivals are equivalent. The weighted means calculated for the sample size calculation suggest a fifteen month survival benefit in favour of delayed cytoreductive surgery.…”

Section: Sample Sizementioning

confidence: 99%

“…Data on the role of delayed cytoreductive surgery after more than four cycles are controversial. While some data have shown survival to be similar to that of patients undergoing interval cytoreductive surgery after three cycles, [2][3][4][5][6][7][8] others have reported poorer prognosis of delayed surgery. [9][10][11][12] Conflicting data are due to selection biases such as heterogeneous inclusion criteria, small sample sizes and retrospective study designs.…”

Section: Introductionmentioning

confidence: 99%

Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)

Gaba

Ash

Blyuss

et al. 2022

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundThe Global Gynecological Oncology Surgical Outcomes Collaborative (GO SOAR) has developed a network of gynecological oncology surgeons, surgical departments, and other interested parties that have the long-term ability to collaborate on outcome studies. Presented is the protocol for the GO SOAR2 study.Primary ObjectivesTo compare survival following interval and delayed cytoreductive surgery, between delayed cytoreductive surgery and no surgery (chemotherapy alone); and international variations in access to cytoreductive surgery for women with stage III–IV epithelial ovarian cancer.Study HypothesesThere is no difference in survival following interval and delayed cytoreductive surgery; there is poorer survival with no surgery compared with delayed cytoreductive surgery; and there are international disparities in prevalent practice and access to cytoreductive surgery in women with stage III–IV epithelial ovarian cancer.Trial DesignInternational, multicenter, mixed-methods cohort study. Participating centers, will review medical charts/electronic records of patients who had been consecutively diagnosed with stage III–IV ovarian cancer between January 1, 2006 and December 31, 2021. Qualitative interviews will be conducted to identify factors determining international variations in prevalent practice and access to cytoreductive surgery.Major Inclusion/Exclusion CriteriaInclusion criteria include women with stage III–IV epithelial ovarian cancer, undergoing interval (after 3–4 cycles of chemotherapy) or delayed (≥5 cycles of chemotherapy) cytoreductive surgeries or no cytoreductive surgery (≥5 cycles of chemotherapy alone).Primary EndpointsOverall survival (defined from date of diagnosis to date of death); progression-free survival (defined from date of diagnosis to date of first recurrence); facilitator/barriers to prevalent practice and access to cytoreductive surgery.Sample SizeIn order to determine whether there is a difference in survival following interval and delayed cytoreductive surgery and no surgery, data will be abstracted from 1000 patients.Estimated Dates for Completing Accrual and Presenting ResultsIt is estimated that recruitment will be completed by 2023, and results published by 2024.Trial RegistrationNCT05523804

show abstract

Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study

Cited by 16 publications

References 37 publications

MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A

MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A

Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer

Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)

Contact Info

Product

Resources

About